Trials / Completed
CompletedNCT01703923
An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough
An Exploratory, Randomized, Placebo-Controlled, Double-Blind, Crossover Study of FP01 Lozenges in Subjects With Chronic Refractory Cough
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Avalo Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the antitussive effect size and dose response of FP01 lozenges in subjects with chronic cough and to demonstrate the safety and tolerability of FP01 lozenges in subjects with chronic cough.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FP01 | |
| DRUG | placebo |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2012-10-11
- Last updated
- 2014-11-05
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01703923. Inclusion in this directory is not an endorsement.